Evidence map›Paper›PMID 38961134›Full record

ArticleScientific reports2024

Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis.

Theresa L Montgomery, Qin Wang, Ali Mirza, Deanna Dwyer, Qi Wu, Catherine A Dowling, Jacob W S Martens, Jennifer Yang, Dimitry N Krementsov, Yang Mao-Draayer

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Theresa L MontgomeryDepartment of Biomedical and Health Sciences, University of Vermont, Burlington, VT, 05401, USA.ORCID 0000-0002-0950-9618
Qin WangAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Ali MirzaPharmacoepidemiology in Multiple Sclerosis Research Group, The University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
Deanna DwyerAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Qi WuAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Catherine A DowlingAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Jacob W S MartensAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Jennifer YangAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Dimitry N KrementsovDepartment of Biomedical and Health Sciences, University of Vermont, Burlington, VT, 05401, USA. Dimitry.Krementsov@uvm.edu.
Yang Mao-DraayerAutoimmunity Center of Excellence, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. yangmaodraayer@gmail.com.

Funding

Interactions Between Host Genetics and the Gut Microbiome in CNS AutoimmunityR01NS097596 · NINDS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI KREMENTSOV, DIMITRY N · 2017 to 2021
$1.7M
University of Michigan Clinical Autoimmunity Center of ExcellenceUM1AI144298 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN, KHANNA, DINESH · 2019 to 2023
$546k
University of Michigan Autoimmunity Center of Excellence, Clinical Research ProgrUM1AI110557 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FOX, DAVID ALAN · 2014 to 2018
$543k
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) UM1-AI110557-05Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) UM1-AI144298-01NIAID NIH HHS UM1 AI110557NIAID NIH HHS UM1 AI144298NINDS NIH HHS R01 NS097596
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Clinical presentation and disease course are highly heterogeneous. Typically, disease progression occurs over time and is characterized by the gradual accumulation of disability. The risk of developing MS is driven by complex interactions between genetic and environmental factors, including the gut microbiome. How the commensal gut microbiota impacts disease severity and progression over time remains unknown. In a longitudinal study, disability status and associated clinical features in 58 MS patients were tracked over 4.2 ± 0.98 years, and the baseline fecal gut microbiome was characterized via 16S amplicon sequencing. Progressor status, defined as patients with an increase in Expanded Disability Status Scale (EDSS), were correlated with features of the gut microbiome to determine candidate microbiota associated with risk of MS disease progression. We found no overt differences in microbial community diversity and overall structure between MS patients exhibiting disease progression and non-progressors. However, a total of 41 bacterial species were associated with worsening disease, including a marked depletion in Akkermansia, Lachnospiraceae, and Oscillospiraceae, with an expansion of Alloprevotella, Prevotella-9, and Rhodospirillales. Analysis of the metabolic potential of the inferred metagenome from taxa associated with progression revealed enrichment in oxidative stress-inducing aerobic respiration at the expense of microbial vitamin K

Indexed as

Disease ProgressionGastrointestinal MicrobiomeMultiple SclerosisAdultFecesFemaleHumansLongitudinal StudiesMaleMiddle AgedRNA, Ribosomal, 16SSeverity of Illness IndexRNA, Ribosomal, 16SAkkermansiaBacterial metabolismGut microbiotaMultiple sclerosisProgressionVitamin K

Identifiers

PMID38961134
PMCPMC11222390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.